Journal
UROLOGY
Volume 89, Issue -, Pages 27-32Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urology.2015.11.034
Keywords
-
Categories
Funding
- AbbVie
- Bayer
- Clarus
- Endo
- Eli Lilly
- Pfizer
Ask authors/readers for more resources
Testosterone therapy (TTh) has become highly controversial. There are important health consequences of testosterone deficiency, and meaningful benefits with treatment. There is level 1 evidence that TTh improves sexual function and desire, body composition, and bone density. Concerns regarding cardiovascular risk were based on two deeply flawed retrospective studies and are contradicted by dozens of studies showing cardiovascular benefits of TTh or higher endogenous testosterone, including placebo-controlled studies in men with known heart disease (angina, heart failure). Prostate cancer should no longer be considered a risk of TTh. Testosterone is neither scourge nor panacea-it is just good medicine. (C) 2016 Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available